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A Randomized, Controlled Trial of Financial Incentives for Smoking Cessation.
Abstract
BACKGROUND: Smoking is the leading preventable cause of premature death in the United States.
Previous studies of financial incentives for smoking cessation in work settings have not shown that such
incentives have significant effects on cessation rates, but these studies have had limited power, and the
incentives used may have been insufficient.
METHODS: We randomly assigned 878 employees of a multinational company based in the United States
to receive information about smoking-cessation programs (442 employees) or to receive information
about programs plus financial incentives (436 employees). The financial incentives were $100 for
completion of a smoking-cessation program, $250 for cessation of smoking within 6 months after study
enrollment, as confirmed by a biochemical test, and $400 for abstinence for an additional 6 months after
the initial cessation, as confirmed by a biochemical test. Individual participants were stratified according
to work site, heavy or nonheavy smoking, and income. The primary end point was smoking cessation 9 or
12 months after enrollment, depending on whether initial cessation was reported at 3 or 6 months.
Secondary end points were smoking cessation within the first 6 months after enrollment and rates of
participation in and completion of smoking-cessation programs.
RESULTS: The incentive group had significantly higher rates of smoking cessation than did the
information-only group 9 or 12 months after enrollment (14.7% vs. 5.0%, P
CONCLUSIONS: In this study of employees of one large company, financial incentives for smoking
cessation significantly increased the rates of smoking cessation. (ClinicalTrials.gov number,
NCT00128375.)
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A Randomized, Controlled Trial of Financial
Incentives for Smoking Cessation
Kevin G. Volpp, M.D., Ph.D., Andrea B. Troxel, Sc.D., Mark V. Pauly, Ph.D.,
Henry A. Glick, Ph.D., Andrea Puig, B.A., David A. Asch, M.D., M.B.A.,
Robert Galvin, M.D., M.B.A., Jingsan Zhu, M.B.A., Fei Wan, M.S.,
Jill DeGuzman, B.S., Elizabeth Corbett, M.L.S., Janet Weiner, M.P.H.,
and Janet Audrain-McGovern, Ph.D.

a bs t r ac t
Background

Smoking is the leading preventable cause of premature death in the United States.
Previous studies of financial incentives for smoking cessation in work settings have
not shown that such incentives have significant effects on cessation rates, but these
studies have had limited power, and the incentives used may have been insufficient.
Methods

We randomly assigned 878 employees of a multinational company based in the United States to receive information about smoking-cessation programs (442 employees)
or to receive information about programs plus financial incentives (436 employees).
The financial incentives were $100 for completion of a smoking-cessation program,
$250 for cessation of smoking within 6 months after study enrollment, as confirmed
by a biochemical test, and $400 for abstinence for an additional 6 months after the
initial cessation, as confirmed by a biochemical test. Individual participants were
stratified according to work site, heavy or nonheavy smoking, and income. The primary end point was smoking cessation 9 or 12 months after enrollment, depending
on whether initial cessation was reported at 3 or 6 months. Secondary end points
were smoking cessation within the first 6 months after enrollment and rates of participation in and completion of smoking-cessation programs.
Results

The incentive group had significantly higher rates of smoking cessation than did
the information-only group 9 or 12 months after enrollment (14.7% vs. 5.0%, P<0.001)
and 15 or 18 months after enrollment (9.4% vs. 3.6%, P<0.001). Incentive-group participants also had significantly higher rates of enrollment in a smoking-cessation
program (15.4% vs. 5.4%, P<0.001), completion of a smoking-cessation program (10.8%
vs. 2.5%, P<0.001), and smoking cessation within the first 6 months after enrollment (20.9% vs. 11.8%, P<0.001).
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Conclusions

In this study of employees of one large company, financial incentives for smoking
cessation significantly increased the rates of smoking cessation. (ClinicalTrials.gov
number, NCT00128375.)
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moking remains the leading preventable cause of premature death in the
United States, accounting for approximately
438,000 deaths each year.1 Seventy percent of
smokers report that they want to quit,2 but annually only 2 to 3% of smokers succeed.3,4 Although
smoking-cessation programs and pharmacologic
therapies have been associated with higher rates
of cessation, rates of participation in such programs and use of such therapies are low.5,6
Work sites offer a promising venue for encouraging smoking cessation because employers are
likely to bear many of the excess health care costs
and productivity losses that are due to missed
work among smokers. In addition, existing channels of communication can be used to reach smokers and reinforce healthful behavior choices. Previous studies have shown that providing smokers
with financial incentives to stop smoking increases enrollment in smoking-cessation programs and
short-term cessation rates,7-10 but the studies have
not shown significant increases in long-term cessation rates. Similarly, studies of financial-incentive
programs in work settings have not shown significant differences in long-term cessation rates,11
though the studies generally were limited by small
sample sizes and weak financial incentives.
In this randomized, controlled trial involving
employees at a large, multinational company based
in the United States, we tested the effectiveness
of a financial incentive of up to $750 in improving
long-term rates of smoking cessation.

Me thods
Study Population

We recruited study participants from February
2005 through November 2006 among employees
at company work sites throughout the United
States. Potential participants were identified with
the use of a survey that asked employees about
their smoking habits, their use of other tobacco
products, and their willingness to be contacted by
researchers from the University of Pennsylvania
about participation in a smoking-cessation study.
These surveys were distributed through the firm’s
intranet and, at sites with high proportions of employees who did not have intranet access, through
on-site recruiting. Employees were eligible to participate if they were at least 18 years of age and if
they reported that they were currently smoking
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five or more cigarettes per day. Employees were
not included in the study if they were currently
using tobacco products other than cigarettes or if
they planned to leave the firm within 18 months.
All participants were followed for at least 12
months; only those with a confirmed negative result within the first 12 months on a cotinine test,
a test that is used for biochemical verification of
self-reported abstinence, were followed for an additional 6 months.
Study Protocol

The protocol was approved by the institutional review board at the University of Pennsylvania, and
all participants provided written informed consent
before randomization. All study participants received information about community-based smoking-cessation resources within 20 miles of their
work site, as well as the standard health benefits
provided by the firm, such as coverage of physician visits and bupropion or other drugs prescribed to promote cessation of tobacco use. Participants in the incentive group were also informed
that they would receive financial incentives for
completion of a community-based smoking-cessation program ($100); for smoking cessation,
confirmed with the use of a cotinine test, within
6 months after study enrollment ($250); and for
continued abstinence for an additional 6 months
after the initial cessation ($400).
All participants were contacted 3 months after
enrollment and asked whether they had stopped
smoking. Participants who reported complete abstinence (not even a puff of a cigarette) for at least
7 days before being contacted were interviewed
so that we could obtain a more extensive assessment of smoking behavior. Participants who did
not report complete abstinence were recontacted
3 months later (i.e., 6 months after enrollment)
for the full follow-up assessment. Six months
after completing their first full interview (i.e.,
at 9 months for those who reported quitting at
3 months; at 12 months for those who were interviewed at 6 months), everyone was interviewed
again. Participants who reported during any follow-up interview that they had stopped smoking
were asked to provide a saliva or urine sample for
confirmation of smoking cessation with the use
of a cotinine test. Participants with negative results
of cotinine tests at both the interview conducted
at 3 or 6 months and the interview conducted at
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9 or 12 months were also interviewed 12 months
after completion of their initial full interview (i.e.,
at 15 or 18 months).
Participants received $20 per interview for participating in telephone interviews at baseline, at
3 or 6 months, at 9 or 12 months, and at 15 or 18
months. After each interview, participants who
reported that they had stopped smoking received
$25 for submitting a sample for biochemical verification of the cotinine level.

Table 1. Characteristics of the Study Participants.*
Characteristic
Mean age (yr)

44.4

45.5

Male sex (%)

64.9

65.6

White

89.3

91.5

Black

5.2

4.4

Hispanic

4.1

4.1

Other

5.4

4.1

High school or lower

25.6

25.2

Some college or completion of college

39.6

40.8

Beyond college

34.8

33.9

Race or ethnic group (%)†

Randomization Procedures

Participants were randomly assigned to a study
group after they provided informed consent. Randomization was performed in permuted blocks
of four and was stratified according to work site,
income (<200%, 200 to 500%, or >500% of the
federal poverty level, which was $9,800 for a single person and $20,000 for a family of four in
2006), and heavy or nonheavy smoking (with heavy
smoking defined as two or more packs of cigarettes per day). The randomized assignments were
concealed until all eligibility criteria had been
entered in an electronic tracking system; however, blinding could not be maintained after this
point because of the nature of the intervention.

Control Group Incentive Group
(N = 442)
(N = 436)

Level of education (%)

Income (%)
<200% of the poverty level

1.6

1.8

200–500% of the poverty level

34.6

32.1

>500% of the poverty level

63.8

66.1

Mean cigarettes per day (no.)

19.7

20.1

Smoking >2 packs per day (%)

6.1

5.1

Mean previous attempts to quit (no.)

6.7

5.7

Smoking habits

Stage of change (%)‡

Assessments of End Points

The primary end point was the participant’s selfreport of abstinence at both 3 and 9 months or at
both 6 and 12 months after study enrollment.
Abstinence was biochemically confirmed by a negative result of a cotinine test performed on a saliva or urine sample. Self-reported continuous abstinence from all tobacco products was defined
as abstinence for a minimum of 7 days before the
3- or 6-month interview (point prevalence) and
abstinence for the duration of the period from
the 3- or 6-month interview to the 9- or 12-month
interview (prevalence of prolonged abstinence).
Secondary end points included enrollment in
a smoking-cessation program; completion of a
smoking-cessation program; rates of smoking cessation within 6 months after study enrollment;
and rates of smoking cessation at 3, 9, and 15
months or 6, 12, and 18 months after study enrollment. Participants were classified as having
completed the smoking-cessation program if they
provided a certificate of completion from the
sponsoring organization.
All follow-up assessments were conducted with
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Precontemplation

15.6

15.1

Contemplation

63.8

67.0

Preparation

20.6

17.9

Self-assessed health (%)
Poor

2.0

1.2

Fair

9.3

8.5

Good

32.1

33.7

Very good

45.9

42.7

Excellent

10.6

14.0

<6

68.1

66.5

≥6

31.9

33.5

Fagerström score for nicotine dependence
(%)§

* There were no significant differences between the control and incentive
groups for any of the variables listed.
† Race or ethnic group was self-reported. One participant in the control group
did not report race or ethnic group and therefore was not included in the denominator for the percentages.
‡ Stage of change refers to the smoker’s readiness, at baseline, to quit, as defined by DiClemente et al.16 and Prochaska et al.17
§ The Fagerström Test for Nicotine Dependence14 has a range of 0 to 10, with
higher scores indicating more nicotine dependence; a score of 6 or greater
was used to classify participants as highly dependent on nicotine.15
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1903 Patients were assessed for eligibility

1025 Were excluded
771 Were ineligible
254 Did not give consent

878 Underwent randomization

442 Were assigned to control
group

436 Were assigned to incentive
group

47 Were lost to follow-up
by 6 mo

12 Withdrew by 6 mo

50 Were lost to follow-up
by 6 mo

16 Withdrew by 6 mo

35 Were lost to follow-up
between 6 and 12 mo

12 Withdrew between
6 and 12 mo

43 Were lost to follow-up
between 6 and 12 mo

13 Withdrew between
6 and 12 mo

2 Were lost to follow-up
between 12 and 18 mo

0 Withdrew between
12 and 18 mo

4 Were lost to follow-up
between 12 and 18 mo

1 Withdrew between
12 and 18 mo

Figure 1. Assessment for Eligibility, Randomization, and Follow-up.
ICM
REG F

AUTHOR: Volpp

RETAKE

FIGURE: 1 of 2

1st
2nd
3rd

at the firm and, at small work
the use of a telephone interview.CASE
Self-reported ces- promotion staff
Revised
4-C did not
sites that
sation was verified by saliva cotinine
tests (with Line
EMail
SIZE have onsite health facilities,
ARTIST: ts
H/Tcontract
33p9
through
with Examination Management
a cotinine level of <15 ng per milliliter
considered H/T
Enon
Combo
12
Services
(Scottsdale,
AZ). Participants’ identities
to be an indication of smoking cessation)AUTHOR,
or by PLEASE
NOTE:
has per
beenmilredrawn were
and type
has been reset.
confirmed
and samples were analyzed at the
urine cotinine tests (with a level ofFigure
<2 ng
Please check carefully.
liliter considered to be an indication of smoking Clinical Pharmacology Laboratory at the Univer13
tests36005
were used only sity of California,
San Francisco.
cessation). Urine cotinine JOB:
ISSUE: 01-29-09
in the case of participants who were using nicotine-replacement therapy, in whom testing of anab Baseline Variables
asine and anatabine levels in the urine was per- The pretreatment level of nicotine dependence was
formed. Participants who reported abstinence but assessed according to the number of cigarettes
who had saliva or urine cotinine levels above the smoked per day, the number of years of smoking,
cutoff points were classified as smokers. Partici- and the score on the Fagerström Test for Nicopants who were lost to follow-up were classified tine Dependence14 (which has a range of 0 to 10,
as relapsed smokers.
with higher scores indicating more nicotine deThe collection of samples was coordinated by pendence); participants with a score of 6 or greater
the study staff in conjunction with the health- were classified as highly dependent on nicotine.15
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Table 2. Smoking-Cessation End Points According to Group Assignment.*
Control Group
(N = 442)

End Point

Incentive Group
(N = 436)

P Value

no. (%)
Enrollment in smoking-cessation program
Participation in program

24 (5.4)

67 (15.4)

<0.001

Completion of program

11 (2.5)

47 (10.8)

<0.001

Self-reported

62 (14.0)

102 (23.4)

<0.001

Confirmed

52 (11.8)

91 (20.9)

<0.001

No sample submitted

9 (2.0)

9 (2.1)

0.79

Positive sample submitted

1 (0.2)

2 (0.5)

0.56

Self-reported

27 (6.1)

66 (15.1)

0.002

Confirmed

22 (5.0)

64 (14.7)

<0.001

5 (1.1)

2 (0.5)

0.06

Smoking cessation at 3 or 6 mo

Smoking cessation at 3 or 6 mo with continued abstinence
through 9 or 12 mo

No sample submitted
Positive sample submitted

0

Self-reported relapse

0

21 (4.8)

21 (4.8)

0.96

Self-reported

17 (3.8)

47 (10.8)

<0.001

Confirmed

16 (3.6)

41 (9.4)

<0.001
0.03

Continued abstinence at 15 or 18 mo among participants
who quit at 3 or 6 mo and remained abstinent
through 9 or 12 mo

No sample submitted

1 (0.2)

6 (1.4)

Positive sample submitted

0

0

Self-reported relapse

3 (0.7)

12 (2.8)

0.02

* Smoking cessation was confirmed by means of a negative result on a cotinine test.

We also collected information on income, work
site, baseline health status, and interest in quitting, as measured by baseline readiness to stop
smoking (i.e., the “stage of change,” as defined by
DiClemente et al.16 and Prochaska et al.17).
Statistical Analysis

The primary analysis was an unadjusted intentionto-treat analysis of the difference in biochemically
confirmed cessation rates between the incentive
and control groups at both 3 and 9 months or at
both 6 and 12 months. The analysis was performed
with the use of Pearson’s chi-square test, or with
the use of Fisher’s exact test, if there were five or
fewer participants per cell. We used a similar approach to estimate differences in rates of cessa-

n engl j med 360;7

tion within 6 months after enrollment; rates of
enrollment in and completion of smoking-cessation programs; and cessation rates at 3, 9, and 15
months or 6, 12, and 18 months after study enrollment. Unadjusted odds ratios for cessation were
estimated and were compared with odds ratios
that were adjusted for the stratification variables
(work site, degree of nicotine dependence, and income) as well as the set of baseline covariates
shown in Table 1; variable-selection methods were
not applied. The similarity of the study groups with
respect to covariates at baseline was analyzed by
the chi-square test for categorical variables and
the Student’s t-test or Wilcoxon rank-sum test for
continuous variables, as appropriate.
Although subgroup analyses were not prespeci-
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Table 3. Odds Ratios for Long-Term (9- or 12-Month) Smoking Cessation.
Variable

Odds Ratio (95% CI)

P Value

3.28 (1.98–5.44)

<0.001

Unadjusted model
Incentive group
Control group

1.00

Model adjusted for stratification variables only
Study group

<0.001

Incentive

3.19 (1.91–5.30)

Control

1.00

Work site*

0.12

Smoking status†

0.15

Heavy

0.34 (0.08–1.45)

Nonheavy

1.00

Poverty level

0.02

>500% of the poverty level

0.96 (0.20–4.63)

200–500% of the poverty level

0.43 (0.08–2.16)

<200% of the poverty level

1.00

Model adjusted for all variables‡
Study group

<0.001

Incentive

3.16 (1.88–5.32)

Control

1.00

Work site*

0.20

Age

0.87

≥40 yr

1.05 (0.58–1.90)

<40 yr

1.00

Sex

0.39
Male

0.80 (0.48–1.33)

Female

1.00

Race

0.69

Black

1.02 (0.32–3.20)

White

1.00

Other

0.50 (0.10–2.44)

Ethnic group

0.80

Hispanic

1.20 (0.30–4.88)

Non-Hispanic

1.00

Level of education

0.69

Beyond college

0.92 (0.49–1.74)

College

0.78 (0.42–1.43)

High school or less

1.00

Poverty level

0.04

>500% of the poverty level

1.03 (0.18–5.79)

200–500% of the poverty level

0.48 (0.08–2.75)

<200% of the poverty level

704
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Table 3. (Continued.)
Variable

Odds Ratio (95% CI)

P Value

Smoking status†

0.20

Heavy

0.38 (0.09–1.67)

Nonheavy

1.00

Previous attempts to stop smoking

0.09

≥5 (top third)

2.00 (1.08–3.71)

3 or 4 (middle third)

1.58 (0.81–3.06)

1 or 2 (bottom third)

1.00

Stage of change§

0.10

Preparation

2.61 (1.02–6.62)

Contemplation

1.64 (0.71–3.83)

Precontemplation

1.00

Self-reported health

0.37

Excellent

1.85 (0.21–16.54)

Very good

1.14 (0.13–9.66)

Good

1.09 (0.13–9.37)

Fair

0.58 (0.06–6.08)

Poor

1.00

* Odds ratios for work-site groups are not reported, owing to the large number of sites included.
† Heavy smoking was defined as 40 cigarettes or more per day.
‡ One study participant was not included in this analysis, owing to missing data on race or ethnic group.
§ Stage of change refers to the smoker’s readiness to quit, as defined by DiClemente et al.16 and Prochaska et al.17

fied, we looked at cessation rates in subgroups
that were defined by seven baseline variables: sex,
income (<200%, 200 to 500%, and >500% of the
federal poverty level), heavy smoking (≥2 packs per
day) or nonheavy smoking, number of previous
attempts to quit (0 to 2, 3 or 4, or ≥5), stage of
quitting as defined by Prochaska et al.17 (precontemplation, contemplation, or preparation), selfassessed health (poor, fair, good, very good, or
excellent), and nicotine dependence as assessed
by the score on the Fagerström Test for Nicotine
Dependence (<6 or ≥6). The homogeneity of the
association (i.e., interaction) between the group
assignment and cessation rates across subgroups
was assessed with the use of the Cochran–Mantel–
Haenszel test. Within each subgroup, rates of cessation in the incentive and control groups were
compared with the use of chi-square tests.
Our power calculations were based on expected
12-month cessation rates of 3.0% in the control
group and 9.4% in the incentive group. To have
80% power to show a difference between groups,
with a 1% two-sided type I error, we needed to
have 360 participants in each group; we increased

n engl j med 360;7

that number by 15%, to 425 in each group, to
account for loss to follow-up resulting from expected employee turnover. No interim analyses
were planned or conducted. All reported P values
are two-sided and were not adjusted for multiple
comparisons.

R e sult s
Figure 1 shows the numbers of subjects who were
screened and who participated in the study intervention and follow-up. Of the 1903 people who
initially expressed interest in participating, 878
(46%) were enrolled; 436 participants were randomly assigned to the incentive group, and 442
to the control group. Demographic characteristics,
smoking behavior, degree of nicotine dependence,
readiness to quit, and health status were similar
in the incentive and control groups (Table 1). Participants in both groups smoked approximately
one pack of cigarettes per day, and approximately
5 to 6% of the participants were heavy smokers.
The majority of the sample had incomes that were
greater than 500% of the poverty level, and ap-
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Incentive
Group

Odds Ratio (95% CI)

no. who quit/total no.
Sex
Male
Female
Poverty level
<200% of poverty level
200–500% of poverty level
>500% of poverty level
Smoking status
Nonheavy
Heavy (>2 packs/day)
Average no. of previous attempts to quit
0–2 (bottom third)
3–4 (middle third)
5–200 (top third)
Stage of change
Precontemplation
Contemplation
Preparation
Self-assessed health
Poor
Fair
Good
Very good
Excellent
Fagerström score for nicotine dependence
<6
≥6

15/287
7/155

40/286
24/150

2.95 (1.59–5.47)
4.03 (1.68–9.66)

0/7
7/153
15/282

2/8
10/140
52/288

5.77 (0.23–143.37)
1.60 (0.59–4.34)
3.92 (2.15–7.15)

22/415
0/27

62/414
2/22

3.15 (1.89–5.23)
6.71 (0.31–147.37)

5/170
7/118
10/154

14/152
17/123
33/161

3.35 (1.18–9.53)
2.54 (1.01–6.38)
3.71 (1.76–7.83)

2/69
13/282
7/91

5/66
40/292
19/78

2.75 (0.51–14.68)
3.28 (1.72–6.28)
3.86 (1.53–9.78)

1/9
1/41
5/142
11/203
4/47

0/5
3/37
23/147
27/186
11/61

0.51 (0.02–15.06)
3.53 (0.35–35.52)
5.08 (1.88–13.78)
2.96 (1.43–6.16)
2.37 (0.70–7.97)

17/301
5/141

49/290
15/146

3.40 (1.91–6.05)
3.11 (1.10–8.81)
0.01

0.1

1.0

10

100

1000

Odds Ratio for Cessation (log scale)

Figure 2. Rates of Smoking Cessation in Various Subgroups at 9 or 12 Months.
Stage of change refers to the smoker’s readiness to quit, as defined by DiClemente et al.16 and Prochaska et al.17
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control group (P<0.001) (Table 2). In both the incentive group and the control group, very few of 6 months after study enrollment was 20.9% in the
the participants who reported that they had quit incentive group, as compared with 11.8% in the
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thus were ineligible for financial incentives —
the cotinine-confirmed cessation rates were similar in the incentive and control groups (4.1% and
5.9%, respectively; P = 0.29).
The odds ratios for quitting by 9 or 12 months
(Table 3) were significantly higher in the incentive group than in the control group in the unadjusted model (odds ratio, 3.28; 95% confidence
interval [CI], 1.98 to 5.44), in a logistic-regression
model that adjusted for stratification variables only
(odds ratio, 3.19; 95% CI, 1.91 to 5.30), and in a
model that adjusted for all the variables included
in Table 1 (odds ratio, 3.16; 95% CI, 1.88 to 5.32).
Exploratory Subgroup Analyses

Figure 2 shows 9-month or 12-month cessation
rates stratified according to subgroup. For all subgroups, members of the incentive group had higher cessation rates than members of the control
group. None of the tests for interaction showed
significant differences in this population; instead, the observed patterns showed a consistent
effect of the intervention across numerous characteristics.

Discussion
In this study of employees at a large corporation,
rates of prolonged abstinence from smoking after
9 or 12 months of follow-up were 14.7% in the
group that was eligible for financial incentives and
5.0% in the control group. Rates of prolonged abstinence at 15 or 18 months in the incentive group
remained significantly higher than those in the
control group.
A 2005 Cochrane Collaboration review of financial incentives for smoking cessation in workplace settings concluded that there was insufficient evidence that these incentives are effective.11
One reason for this finding may be that many
previous studies were not designed with samples
that were large enough to detect the differences
we observed. A second reason may be that the incentives used in previous studies have generally
been small (as little as $10 in some of them). Studies have shown that financial-incentive programs
are associated with an increased rate of smoking
cessation in the short term, but the programs reported in these studies were not designed to focus on sustaining high rates over time.7,9 The relationships of the size and structure of incentive
payments to rates of smoking cessation remain

n engl j med 360;7

important empirical questions that need to be
addressed in future research. It is possible that
larger — or smaller — payments by employers
could be more cost-effective in improving smoking-cessation rates. The optimal design of incentive programs for smoking cessation is also an
open question, since extension of the incentives
beyond 12 months may result in higher cessation
rates over a longer period.
The cotinine level, which we used for biochemical verification of 7-day abstinence, is considered
to be the best biomarker of smoking cessation.12
Consistent with the recommendations of the Society for Research on Nicotine and Tobacco, our
primary measure of self-reported cessation at both
9 or 12 months and 15 or 18 months was prolonged abstinence.12 Although prolonged abstinence can be biochemically verified only indirectly
because of the limitations of the cotinine test, it
is likely that the point prevalence is highly correlated with prolonged abstinence 6 months after
short-term quitting was assessed.12
To date, financial incentives within health care
settings have been directed primarily toward providers, through Pay for Performance (P4P) programs. However, given that up to 40% of premature deaths in the United States are due to
unhealthful behaviors such as smoking, poor dietary habits, and sedentary lifestyles,18 incentives
directed toward patients rather than providers may
have greater potential for changing health behaviors.19-21 One approach to encouraging smoking
cessation would be to adjust health-insurance premiums on the basis of smoking status; however,
targeted payments for smoking cessation have the
advantage of being unbundled from health-insurance premiums and thus may be more salient to
people, thereby having a greater influence on behavior.22
The financial benefit to employers of having
their employees stop smoking is estimated to be
about $3,400 per year23 as a result of increased
productivity, decreased absenteeism, and a reduced
incidence of illness. There is also strong evidence
that employees prefer to work for firms that offer
effective and attractive benefit programs.24 However, few employers offer full coverage of smoking-cessation services or cessation programs in
the workplace,8,25,26 partly because a compelling
“business case” for such coverage has not been
made. Notably, neither the financial-incentive intervention nor the control intervention in our study
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included the establishment of a smoking-cessation program; both interventions merely encouraged participants to use existing programs.
The literature on smoking cessation suggests
that most relapses occur within the first month
of cessation, that approximately 90% of relap
ses occur within the first 6 months,27 and that
the likelihood of continuous abstinence over a
20-month period is about 95% for smokers who
quit for 1 year or longer.12 Our finding of relapse
rates between the 9- or 12-month visit and the
15- or 18-month visit (27.3% in the control group
and 35.9% in the incentive group) that appear to
be higher than those reported in the literature
may suggest that relapse rates differ according
to whether smoking cessation occurs in the presence or absence of incentives. However, since the
relapse rates in both the incentive and control
groups differ from those in the literature, and in
view of the relatively small number of participants in our study who quit smoking, we cannot
be confident that the relapse rates do in fact differ from those previously reported.
Because approximately 90% of the enrolled
population was white and the participants had
relatively high education and income levels, our
study may have limited generalizability to employees with lower socioeconomic status than that of
the participants in our study or to members of a
minority racial or ethnic group. In addition, programs that are designed to change behavior may

of

m e dic i n e

have unintended consequences that we could not
observe in our study. However, we think it is unlikely that substantial numbers of people would
start smoking in order to be eligible for such incentive programs. Studies such as this one are
subject to selection bias, in that smokers who voluntarily enroll in these programs may be more
likely (whether they are assigned to the incentive
group or the control group) to quit smoking; it is
difficult to project how effective these programs
would be in a population that included all employees within a given company.
In summary, this study shows that smokingcessation rates among company employees who
were given both information about cessation
programs and financial incentives to quit smoking were significantly higher than the rates among
employees who were given program information
but no financial incentives.
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